Inhibiting the transient receptor potential a1 ion channel
AssigneeEli Lilly and Company
InventorXinyuan Edward WU
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Claims15
1-67. (canceled)
A compound of the formula:
- wherein the compound is of greater than 95% purity,
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- wherein the compound is of greater than 95% purity.
A pharmaceutical composition, comprising a compound of the formula:
- or a pharmaceutically acceptable salt thereof, in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.
A pharmaceutical composition comprising a compound of the formula:
- in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.
A method of treating pain in a subject, comprising administering an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition, comprising a compound of the formula:
- or a pharmaceutically acceptable salt thereof, in a mixture with a pharmaceutically acceptable excipient, diluent, or carrier.
A method of treating pain in a subject, comprising administering an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.